Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company that develops novel T cell engagers and other biologics to engage and activate the immune system for the treatment of cancer and other diseases. The company’s proprietary technology platform, TriTAC, allows for the targeting of multiple tumor antigens simultaneously, potentially enhancing effectiveness and reducing side effects. Harpoon Therapeutics Inc. is headquartered in South San Francisco, California.
